Drug Sponsors

Report: Healthcare companies must embrace new funding sources

Tuesday, November 29, 2016

Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early-stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, said business intelligence provider GBI Research.

[Read More]

Shire to establish rare disease innovation hub in Massachusetts

Wednesday, November 23, 2016

Shire will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire’s lease begins in Q3, 2018, with occupancy anticipated for Q1, 2019.

[Read More]

ContextMedia acquires AccentHealth

Monday, November 21, 2016

ContextMedia, a healthcare decision platform, will acquire AccentHealth, which provides best-in-class patient education at the point of care, in an all-cash purchase. Through this acquisition, ContextMedia becomes the largest healthcare decision platform at the point of care in the U.S., with a rapidly growing reach across clinics, hospitals and health systems. In 2016, ContextMedia has been adding nearly 1% of all practices in the country each month and continues to grow rapidly in pursuit of ubiquitous presence of its healthcare technologies into every consultation room in the world. The company believes it will have a presence in 70% of all practices in the U.S. by 2020.

[Read More]

Seven Bridges to integrate platform with SolveBio

Monday, November 21, 2016

Seven Bridges, a biomedical data analysis company, and SolveBio have announced the integration of their complementary platforms for genomic data analysis. The integration of Seven Bridges’ platform for cloud-based biomedical data analysis with SolveBio enables biotech and pharmaceutical researchers to seamlessly transition from the analysis of large NGS datasets to clinical analysis and interpretation, speeding the progress of their precision medicine initiatives. This integration is available in Seven Bridges’ Public Apps repository, meaning any joint customer may immediately use this end-to-end workflow.

[Read More]

Roche launches global cancer immunotherapy network imCORE

Friday, November 18, 2016

Roche has launched the global cancer immunotherapy Centers of Research Excellence (imCORE) Network. This network brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures for people with cancer. The imCORE Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.

[Read More]

Symcel, TiKa Diagnostics and St. George’s partner

Wednesday, November 9, 2016

Symcel, the company behind a cell-based assay tool for real-time cellular bioenergetic measurements, calScreener, has partnered with TiKa Diagnostics and St. George’s University of London for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The rapid detection of antimicrobial resistance is now crucial to maximize efforts in controlling the prevalence and spread of drug resistant Mycobacterium tuberculosis (Mtb). Moreover, the development of novel agents, such as AMPs, able to combat superbugs and interfere with biofilm formation, has become a key necessity.  

[Read More]

Bridge Medicines launched to advance early technologies

Wednesday, November 2, 2016

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

[Read More]